Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -45.49
- Piotroski Score 4.00
- Grade Hold
- Symbol (TTOO)
- Company T2 Biosystems, Inc.
- Price $1.83
- Changes Percentage (0.55%)
- Change $0.01
- Day Low $1.78
- Day High $1.83
- Year High $33.20
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $5.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $109.92
- Trailing P/E Ratio 0.04
- Forward P/E Ratio 0.04
- P/E Growth 0.04
- Net Income $-50,077,000
Income Statement
Quarterly
Annual
Latest News of TTOO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Gen Z's replaces millennial tribal tattoo trend with cybersigilism...
Gen Z is embracing cybersigilism tattoos, a modern body art trend characterized by sharp, intricate black lines inspired by technology and mysticism. Celebrities like Dua Lipa and Billie Eilish are sp...
By New York Post | 4 days ago -
The prince and the parlor! Prince Harry visits LES tattoo shop with...
Prince Harry visited a high-end tattoo shop in New York City, sparking speculation about him getting inked. The shop owner remained discreet, and sources suggested it was for a project. Despite the ru...
By New York Post | 1 week ago -
LeBron James Debuts Olympic Rings Tattoo Following Gold Medal Win at 2024 Paris Games -- See His New Ink!
After leading Team USA Basketball to their 17th gold win, the 39-year-old basketball star got an Olympic rings tattoo, marking his fourth appearance at the games. He also has a tribute tattoo for Kobe...
By PEOPLE.com | 1 week ago
